St John Mental Health Clinic of Houston

12/08/2023

https://www.jblearning.com/blog/jbl/2023/11/08/filling-schedule-ii-prescriptions-changes-in-federal-law

Rule changes implemented in August expand pharmacy ability to issue partial fills of Schedule II controlled substances and may ease patient hassle in obtaining prescriptions for ADHD medications.

In August 2023, the DEA finalized regulations for partial fills under CARA, which provided long sought clarification for pharmacists, health care providers and politicians.

06/30/2023

Australia is allowing legal access to M**A-assisted therapy, unexpectedly turning itself into a guinea pig ahead of potential FDA approval in the United States.

11/01/2022

https://www.texmed.org/TexasMedicineDetail.aspx?id=60684&_zs=qE6eA1&_zl=BgHt6

The U.S. Food and Drug Administration (FDA) expects a nationwide shortage of Adderall and Adderall IR to extend through the end of the year, following manufacturing delays by the largest producer of Adderall in the country, Teva Pharmaceuticals LLC.

10/04/2022

The next DEA National Rx Take Back Day will take place on Saturday, October 29 from 10 am -2 pm. Use this link to find a location to dispose of unwanted and unused medications.

https://www.dea.gov/takebackday -locator

The drug overdose epidemic in the United States is a clear and present public health, public safety, and national security threat. DEA’s National Prescription Drug Take Back Day reflects DEA’s commitment to Americans’ safety and health, encouraging the public to remove unneeded medications fro...

09/30/2022

A psychiatrist is a medical doctor (an M.D. or D.O.) who specializes in mental health, including substance use disorders. Psychiatrists are qualified to asse...

08/31/2022

https://consumer.healthday.com/b-8-29-adhd-drug-adderall-in-short-supply-2657957236.html

MONDAY, Aug. 29, 2022 (HealthDay News) -- Labor shortages at Teva Pharmaceuticals have made Adderall, a widely used attention-deficit/hyperactivity disorder (ADHD) drug, hard to find in some drugstores.But the U.S. Food and Drug Administration noted that there's no overall shortage of ADHD medicatio...

08/22/2022

Exciting news! First new antidepressant approved in 3 years. More information to come with availability expected towards the end of the year.

https://www.globenewswire.com/news-release/2022/08/19/2501453/33090/en/Axsome-Therapeutics-Announces-FDA-Approval-of-AUVELITY-the-First-and-Only-Oral-NMDA-Receptor-Antagonist-for-the-Treatment-of-Major-Depressive-Disorder-in-Adults.html

AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared...